The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.
SUBJECT TO COMPLETION
PRELIMINARY PROSPECTUS DATED JANUARY 8, 2024
PRELIMINARY PROSPECTUS
C3IS INC.
9,090,909 Units consisting of
Common Shares or Pre-Funded Warrants and Class B-1 Warrants to
purchase Common Shares and Class B-2 Warrants to purchase
Common Shares
(and Common Shares underlying the Pre-Funded Warrants, Class B-1
Warrants and Class B-2 Warrants)
We are offering 9,090,909 Units (the “Units”), each Unit consisting of one share of common stock, par value $0.01 per share (each, a “Common Share”), one half of a Class B-1 warrant to purchase one Common Share (each, a “Class B-1 Warrant”) and one Class B-2 warrant to purchase one Common Share (each, a “Class B-2 Warrant”, and together with the Class B-1 Warrants, the “Class B Warrants”), in each case at an assumed public offering price of $0.66 per Unit, equal to the closing price of our Common Shares on the Nasdaq Capital Market on January 5, 2024. Each Class B-1 Warrant will be immediately exercisable for one Common Share at an assumed exercise price of $ per share (a multiple of 1.5 times the offering price per Unit, assuming an offering price of $ per Unit) and expire five years after the issuance date. Each Class B-2 Warrant will be immediately exercisable for one Common Share at an assumed exercise price of $ per share (a multiple of 1.70 times the offering price per Unit, assuming an offering price of $ per Unit) and expire five years after the issuance date. We are also offering to each purchaser of Units that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the holder, 9.99%) of our outstanding Common Shares immediately following the consummation of this offering, the opportunity to purchase Units consisting of one pre-funded warrant (in lieu of one Common Share) and one half of a Class B-1 Warrant and one Class B-2 Warrant. Subject to limited exceptions, a holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of Common Shares outstanding immediately after giving effect to such exercise. Each pre-funded warrant will be exercisable for one Common Share. The purchase price of each Unit including a pre-funded warrant will be equal to the price per Unit including one Common Share, minus $0.01, and the remaining exercise price of each pre-funded warrant will equal $0.01 per share. The pre-funded warrants will be immediately exercisable (subject to the beneficial ownership cap) and may be exercised at any time until all of the pre-funded warrants are exercised in full. For each Unit including a pre-funded warrant we sell (without regard to any limitation on exercise set forth therein), the number of Units including one Common Share we are offering will be decreased on a one-for-one basis. The Common Shares and pre-funded warrants, if any, can each be purchased in this offering only with the accompanying one half Class B-1 Warrant and one Class B-2 Warrant as part of a Unit, but the components of the Units will immediately separate upon issuance. See “Description of Securities We Are Offering” in this prospectus for more information.
We are also registering the Common Shares included in the Units and the Common Shares issuable from time to time upon exercise of the Class B-1 Warrants, Class B-2 Warrants and pre-funded warrants offered hereby. This prospectus also covers any additional securities that may become issuable by reason of share splits, share dividends or other similar transactions.
Our Common Shares are listed on the Nasdaq Capital Market (“Nasdaq”) and began trading (regular way) on June 22, 2023 under the symbol “CISS”. On January 5, 2024, the closing sale price as reported on Nasdaq of the Common Shares was $0.66 per share. The public offering price of the Units will be determined between us and investors based on market conditions at the time of pricing, and may be at a discount to the then current market price of our Common Shares. The assumed public offering price and related Class B-1 Warrant and Class B-2 Warrant exercise prices used throughout this prospectus may not be indicative of the actual public offering price. The actual public offering price may be based upon a number of factors, including our history and our prospects, the industry in which we operate, our past and present operating results, the previous experience of our executive officers and the general condition of the securities markets at the time of this offering. There is no established trading market for the pre-funded warrants, Class B-1 Warrants, or Class B-2 Warrants and we do not expect an active trading market to develop. We do not intend to list the pre-funded warrants, Class B-1 Warrants, or Class B-2 Warrants on any securities exchange or other trading market. Without an active trading market, the liquidity of these securities will be limited.
We are an “emerging growth company” as that term is used in the Securities Act of 1933, as amended (the “Securities Act”), and, as such, we may elect to comply with certain reduced public company reporting requirements. See “Risk Factors” and “Prospectus Summary—Implications of Being an Emerging Growth Company.”
Investing in our securities involves risks. See “Risk Factors” beginning on page 18 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.
| | | | | | | | | | | | |
| | Per Unit including Common Shares | | | Per Unit including Pre-Funded Warrants | | | Total(2) | |
Public offering price(1) | | $ | | | | $ | | | | $ | | |
Underwriting Discounts and Commissions(1) | | $ | | | | $ | | | | $ | | |
Proceeds, before expenses, to us(1) | | $ | | | | $ | | | | $ | | |
(1) | See “Underwriting” beginning on page 140 of this prospectus for additional information regarding underwriter compensation. |
(2) | Assumes no pre-funded warrants are issued and all units issued in the offering include Common Shares. |
We have granted the underwriters an option for a period of up to 45 days to purchase up to 1,363,636 additional Common Shares and/or pre-funded warrants and/or up to an additional 681,818 Class B-1 Warrants and/or 1,363,636 Class B-2 Warrants. The underwriter may exercise the over-allotment option with respect to Common Shares only, Pre-Funded Warrants only, Class B-1 Warrants only, Class B-2 Warrants only, or any combination thereof.
The underwriters expect to deliver the securities to purchasers on or about , 2024.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Aegis Capital Corp.
Prospectus dated , 2024.